Rofecoxib

Overview

Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC 50 s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC 50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).

Application

Products | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Depression | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > COX

Product Information

• Catalog No.: HY-17372
• CAS No.: 162011-90-7
• Molecular Formula: C17H14O4S
• Molecular Weight: 314.36
• Purity: 99.89%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution
• Availability: In-stock

Source

Original product source